| Tuesday June 6, 2017 |
| 13:00 | Registration |
|
| 14:00 | Welcome Address |
|
| Session 1: Biophysical Techniques for the Study of Integral Membrane Proteins |
|
| Session Chair |
Dr Ursula EGNER
(BAYER HEALTHCARE, Berlin, Germany) |
| 14:15 | Use of Mini-G Proteins to Study the Activate State of G Protein-Coupled Receptors (PL01) |
Dr Chris TATE
(MRC LABORATORY OF MOLECULAR BIOLOGY, Cambridge, United Kingdom) |
| 15:00 | Biophysical Analysis to Aid and Complement Structure Based Drug Design for GPCRS (OC01) |
Dr Carmen DREGGER
(HEPTARES THERAPEUTICS, Welwyn Garden City, United Kingdom) |
| 15:25 | Method for Rapid Optimization of Recombinant GPCR Protein Expression and Stability Using Virus-Like Particles (OC02) |
Dr Kathleen AERTGEERTS
(DART NEUROSCIENCE, San Diego, United States) |
| 15:50 | Coffee Break |
|
| 16:20 | Enabling Biophysics on Membrane Proteins Targets : Example of a Human Nucleoside Transporter (PL02) |
Dr Nicolas BOCQUET
(LEADXPRO AG, Villigen, Switzerland) |
| 17:05 | Exhibitor Short Presentation: Creoptix
The Wave of the Future in Kinetics |
Dr Matyas VEGH
(CREOPTIX AG, Wädenswil, Switzerland) |
| 17:15 | Exhibitor Short Presentation: Synthelis
Cell-free technology, expertise and services for your project in structural biology |
Mrs Safia EZZINE
(SYNTHELIS, La Tronche, France) |
| Keynote Lecture |
|
| Chair |
Prof. Rod HUBBARD
(UNIVERSITY OF YORK & VERNALIS, Cambridge, United Kingdom) |
| 17:25 | Allosteric Mechanisms of Signal Transduction Investigated with Pentameric Ligand Gated Ion Channels: Consequences for Drug Design (KL01) |
Prof. Jean-Pierre CHANGEUX
(COLLÈGE DE FRANCE & INSTITUT PASTEUR, Paris, France) |
| 18:25 | Welcome Reception |
|
| 20:00 | End of the Day |
|
| Wednesday June 7, 2017 |
| 08:30 | Registration |
|
| Session 2: Recent Advances in NMR |
|
| Session Chair |
Dr Chun-wa CHUNG
(GLAXOSMITHKLINE, Stevenage, United Kingdom) |
| 09:00 | Study of Protein Folding and Ligand Binding by Pressure Jump NMR (PL03) |
Prof. Ad BAX
(NATIONAL INSTITUTES OF HEALTH, Bethesda, United States) |
| 09:45 | NMR as a Powerful Tool for Identifying Natural Compounds Able to Interfere with ELAV-mRNA Complexes (OC03) |
Dr Francesca VASILE
(UNIVERSITY OF MILANO, Milano, Italy) |
| 10:10 | Coffee Break |
|
| 10:40 | New NMR Tools for Drug Discovery : From Validation to Structure Determination (PL04) |
Dr Alvar GOSSERT
(ETH ZÜRICH, Zürich, Switzerland) |
| Session 3: Hot Topics |
|
| Session Chair |
Dr Sandra JACOB
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland) |
| 11:25 | Biophysical Assays to Answer Evolving Questions in Drug Discovery (OC04) |
Dr Derrick MEINHOLD
(GLAXOSMITHKLINE, Conshohocken, United States) |
| 11:50 | Exhibitor Short Presentation: Sierra Sensors
High-Throughput SPR Screening in Drug Discovery |
Dr Sven MALIK
(SIERRA SENSORS, Hamburg, Germany) |
| 12:00 | Exhibitor Short Presentation: Biodesy
Screening with Structural Insight: High Throughput Measurement of Protein Conformational Change |
Dr Tad GEORGE
(BIODESY, San Francisco, United States) |
| Session 5: Detecting Allosteric Effectors (advanced) |
|
| Session Chair |
Prof. Helena DANIELSON
(UPPSALA UNIVERSITY, Uppsala, Sweden) |
| 12:10 | Surface Plasmon Resonance Based Method to Discriminate Direct Competition and Allosteric Effects in Ternary Systems (OC10) |
Dr Armin RUF
(F. HOFFMANN - LA ROCHE, Basel, Switzerland) |
| 12:35 | Lunch & Networking |
|
| Session 4: Recent Advances in FBDD |
|
| Session Chair |
Prof. Rod HUBBARD
(UNIVERSITY OF YORK & VERNALIS, Cambridge, United Kingdom) |
| 14:00 | FBLD and Biophysics: Better Together (KL02) |
Dr Dan ERLANSON
(CARMOT THERAPEUTICS, San Francisco, United States) |
| 15:00 | XCHEM: A High Throughput in Crystallo Fragment Screening Platform (OC06) |
Dr Alexandre DIAS
(DIAMOND LIGHT SOURCE LTD, Didcot, Oxon, United Kingdom) |
| 15:25 | Fragment Screening against DC-SIGN Identifies Multiple Druggable Secondary Sites (OC07) |
Mr Hannes BAUKMANN
(MAX PLANCK INSTITUTE OF COLLOIDS AND INTERFACES, Potsdam-Golm, Germany) |
| 15:50 | Coffee Break |
|
| 16:20 | Fragment Based Lead Generation – What Drives Success? (PL05) |
Dr Jenny SANDMARK
(ASTRAZENECA, Gothenburg, Sweden) |
| 17:05 | A New Heuristic to Predict 3D Ligand Bound Conformation by Mining PDB Subpockets (OC08) |
Mr Olivier BEQUIGNON
(JANSSEN R&D, Val de Reuil Cedex, France) |
| 17:30 | Exhibitor Short Presentation: Domainex
The MST Approach to Fragment Screening |
Prof. Trevor PERRIOR
(DOMAINEX LIMITED, Cambridge, United Kingdom) |
| 17:40 | Navigating Biophysical Space in Search of Medicines (PL06) |
Dr Glyn WILLIAMS
(ASTEX PHARMACEUTICALS, Cambridge, United Kingdom) |
| Thursday June 8, 2017 |
| Session 5: Detecting Allosteric Effectors |
|
| Session Chair |
Prof. Helena DANIELSON
(UPPSALA UNIVERSITY, Uppsala, Sweden) |
| 09:00 | Large Scale Protein Conformational Motions : From Fundamental Biophysics to Functional Dynamics (PL07) |
Prof. Martin BLACKLEDGE
(IBS - INSTITUT DE BIOLOGIE STRUCTURALE, Grenoble, France) |
| 09:45 | Identifying Allosteric Modifiers of K-RAS Using Second Harmonic Generation (OC09) |
Dr Elizabeth VO
(UCSF, San Francisco, United States) |
| 10:10 | Coffee Break |
|
| 10:40 | Analysis of Allosteric Modulators with Kinetic Fret (OC11) |
Dr Martin REDHEAD
(UCB, Slough, United Kingdom) |
| 11:05 | Spectroscopic Adventures in Orthosteric and Allosteric Inhibition (PL08) |
Dr Richard TAYLOR
(UCB, Slough, United Kingdom) |
| Session 3: Hot Topics (continued) |
|
| Session Chair |
Dr Sandra JACOB
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland) |
| 11:50 | Precision of Biophysical Techniques that Determine Protein? Compound Dissociation Constants, Lessons from our Database of over 700 Ligand Kds Determined by ITC, FTSA(DSF), SPR, and SFA (OC05) |
Prof. Daumantas MATULIS
(INSTITUTE OF BIOTECHNOLOGY, Vilnius, Lithuania) |
| 12:15 | Lunch & Networking |
|
| 13:15 | Poster Session |
|
| Session 6: IDPs and the Dark Proteome |
|
| Session Chair |
Dr Geoff HOLDGATE
(ASTRAZENECA, Macclesfield, United Kingdom) |
| 14:30 | Mechanistic Insights into TSPO and IDPs through NMR (PL09) |
Prof. Markus ZWECKSTETTER
(MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY, Göttingen, Germany) |
| Roundtable Discussion |
|
| 15:15 | Increasing Success in Science by Increasing Diversity: From Methods to Gender |
|
| Session 6: IDPs and the Dark Proteome (continued) |
|
| Session Chair |
Dr Geoff HOLDGATE
(ASTRAZENECA, Macclesfield, United Kingdom) |
| 16:00 | Finding Small-Molecules Inhibitors of the Interaction between the Intrinsically Disordered Androgen Receptor N-Terminal Domain and its Globular Partner RAP74 C-Terminal Domain (OC12) |
Mrs Marta FRIGOLÉ-VIVAS
(INSTITUTE FOR RESEARCH IN BIOMEDICINE (IRB BARCELONA), Barcelona, Spain) |
| 16:25 | Coffee Break |
|
| 16:55 | Systematic Development of Small Molecules Against Aβ Aggregation (PL10) |
Prof. Michele VENDRUSCOLO
(UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom) |
| 17:40 | Poster Prizes |
|
| 17:50 | End of the Day |
|
| 20:00 | Conference Dinner |
|
| Friday June 9, 2017 |
| Session 7: Antibodies and Relatives |
|
| Session Chair |
Dr Jim BRYSON
(BRISTOL-MYERS-SQUIBB R&D, New York, United States) |
| 09:00 | Cutting-Edge Mass Spectrometry Methods for the Multi-Level Structural Characterization of mAbs and ADCs (KL03) |
Dr Alain BECK
(PIERRE FABRE, St Julien-en-Genevois, France) |
| 10:00 | Adnectin Bioconjugates for PET Imaging and Targeted Drug Conjugates (PL11) |
Dr Jim BRYSON
(BRISTOL-MYERS-SQUIBB R&D, New York, United States) |
| 10:45 | Coffee Break |
|
| 11:15 | Exhibitor Short Presentation: Pall ForteBio
Our Label-Free, Real-Time Kinetics Technologies with Microplate Sampling Allow for High-Throughput in Screening & Characterisation of Drug Candidates Including Challenging Matrixes Like Crude Biologicals or Fragments in DMSO |
Mr Attila ARANYOS
(PALL CORPORATION, Saint-Germain-en-Laye, France) |
| 11:25 | Thermal Stabilization and Conformational Trapping of Membrane Transporters by in Vitro Selected Synthetic Nanobodies (PL12) |
Prof. Markus SEEGER
(UNIVERSITY OF ZURICH, Zürich, Switzerland) |
| 12:10 | Closing Remarks and Departure |
|
